That $1.25B Bristol-Myers IDO1 drug? Incyte claims a former staffer stole it
When Bristol-Myers Squibb agreed to pay up to a jaw-dropping $1.25 billion to acquire the fledgling biotech Flexus back in early 2015 for the sole …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
